

DAFTAR PUSTAKA

- Adams PC, Barton JC, 2011. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. *Journal of Hepatology* 55:453–458.
- Al-Azem H, Khan AA, 2012. Hypoparathyroidism. *Best Practice and Research Clinical Endocrinology and Metabolism*. 26:517–522.
- Ashley E, 2012. Ferritin (serum, plasma). *Association for Clinical Biochemistry*. [Online] DOI 1-6. Available from: <http://www.acb.org.uk/Nat%20Lab%20Med%20Hbk/Ferritin.pdf> [Accessed on: 20 Februari 2020]
- Atashi F, Modarressi A, Pepper MS, 2015. The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review. *Stem Cells and Development*. 24:1150–1163.
- Azwar S, 2003. Keterlambatan Pubertas. *Sari Pediatri*. 4:176-179.
- Baldini M, Forti S, Marcon A, Ulivieri FM, Orsatti A, Tampieri B, Airaghi L, Zanaboni L, Cappellini M, 2010. Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. *Annals of Hematology*, Springer Verlag, 89:1207-1213.
- Bandeira LC, Rubin MR, Cusano NE, Bilezikian JP, 2018. Vitamin D and Hypoparathyroidism. *Frontiers of Hormone Research*, 50:114–124.
- Balogh E, Paragh G, Jeney V, 2018. Influence of Iron on Bone Homeostasis. *Pharmaceuticals*. 11:107.
- Beaton MD, Adams PC, 2012. Treatment of hyperferritinemia. *Annals of Hepatology*. 11:294-300.
- Beaton MD, Chakrabarti S, Adams PC, 2014. Inflammation is not the cause of an elevated serum ferritin in non-alcoholic fatty liver disease. *Annals of Hepatology*. 13:353-356.
- Berdoukas V, Farmaki K, Carson S, Wood J, Coates T, 2012. Treating thalassemia major-related iron overload: the role of deferiprone. *Journal of Blood Medicine*. 3:119–129.
- Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O, 2012. Oxidative stress and antioxidant defense. *WAO Journal* 5:9–19.
- Blake GM, Fogelman I, 1997. Technical principles of dual energy x-ray absorptiometry. *Seminar in Nuclear Medicine*. 27:210-228.
- Bogdan AR, Miyazawa M, Hashimoto K, dan Tsuji Y, 2016. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. *Trends in Biochemical Sciences*. 41:3.
- Bordbar M, Haghpanah S, Zekavat OR, Saki F, Bazrafshan A, Bozorgi H, 2019. Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients. *Expert Review of Hematology*. 12:997-1003.

- Brissot P, 2014. Liver Disease. *Guidelines for The Management of Transfusion Dependent Thalassemia (TDT) 3th Edition*. Cappellini MD, Cohen A, Porter J, Taher A and Viprakasit V. Thalassemia International Federation TIF Publication no 20
- Brissot P, Troadec MB, Bardou-Jacquet E, Le Lan C, Jouanolle AM, Deugnier Y, Loreal O, 2008. Current approach to hemochromatosis. *Blood Review*. 22:195-210.
- Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW, 1993. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. *American Journal of Hematology*. 42:81-85.
- Brudevold R, Hole T, Hammerstrom J, 2008. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. *PLoS ONE* 3(10): e3547
- Camaschella C, Poggiali E, 2009. Towards explaining unexplained hyperferritinemia. *Haematologica* 94:307-309.
- Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM, 2011. Osteoporosis quality indicators using healthcare utilization data. *Osteoporosis International*. 22:1335-42.
- Cappellini MD, Pattoneri P, 2009. Oral iron chelators. *Annual Review of Medicine* 60:25-38.
- Cappellini MD, 2014. Guidelines for management of transfusion dependent thalassaemia (TDT). Edisi ke-3, Nicosia, Cyprus: Thalassaemia International Federation.
- Cassara F, Maggio A, 2013. Iron load. *Thalassemia Reports* 3(s1):e5
- Chun JK, 2011. Bone Densitometry. *Seminars in Nuclear Medicine*. 41:220-228.
- Chapin JC, Vogiatzi M, Kleinert D, DeFilippis E, Christos P, Giardina P, 2014. Fracture Prevalence in Adults with Transfusion-Dependent Thalassemia Is Related to Osteoporosis and Age. *Blood*. 124:4902.
- Chen YC, Hsiao JK, Liu HM, Lai IY, Yao M, Hsu SC, 2010. The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. *Toxicology and Applied Pharmacology*. 245:272–279.
- Dahlan MS, 2009. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan (edisi 3). Salemba Medika
- Deugnier Y, Turlin B, 2007. Pathology of hepatic iron overload. *World Journal of Gastroenterology*. 13:4755-4760.
- toumba O, Vidal C, Duque G, 2012. Aging and bone loss: new insights for the clinician. *Therapeutic Advances in Musculoskeletal Disease*. 4:61–76.
- Dharmesh CS, Anita A, Purnima K, Poonam W, Jyoti B, 2017. Overview On Thalassemias: A Review Article. *Medico Research Chronicles*. 4:325-337.
- Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, Kanokkantapong C, Rajatanavin R, 2003. Abnormalities in Bone Mineral

- Density and Bone Histology in Thalassemia. *American Society for Bone and Mineral Research*. 18:9.
- Doyard M, Fatih, N, Monnier A, Island, ML, Aubry M, Leroyer P, 2012. Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells. *Osteoporosis International*. 23:2435–2445.
- Gomber S, Dewan P, 2006. Physical growth patterns and dental caries in thalassemia. *Indian Pediatrics*. 43:1064–1069.
- Giusti A, 2014. Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. *Journal Bone Mineral Metabolism*. 32:606–615.
- Gurevitch O, Slavin S, 2006. The hematological etiology of osteoporosis. *Medical Hypotheses*. 67:729–735.
- Haidar, R., Musallam, KM., Taher, AT., 2011. Bone disease and skeletal complications in patients with beta thalassemia major. *Bone*. 48: 425–432.
- Hamidah A, Arini MI, Zarina AL, Zulkifli SZ, Jamal R. Growth velocity in transfusion dependent prepubertal thalassemia patients: results from a thalassemia center in Malaysia. *The Southeast Asian Journal of Tropical Medicine and Public Health*. 39:900–905.
- Hanley P, Lord K, dan Bauer AJ, 2016. ‘Thyroid Disorders in Children and Adolescents’. *JAMA Pediatric*, 170:1008-1019.
- Hershko C, Link G, Konijn AM, Cabantchik ZI, 2005. Objectives and mechanism of iron chelation therapy. *Annals of the New York Academy of Sciences*. 1054:124-135.
- Ibrahim HM, Hassan A, George E, Sim GA, Othman IS, Ghazali IMM, Foo JLK, Wong L, Razali RH, Sahid SM, Wan Mokhtar WZH, Lee CL, Zain FM, Hassan H, Osman IF, Yeow Hua JH, Teik KW, Bee OG, Bahrin S, Ing SL, Leng YS, 2009. Clinical practice guidelines – management of transfusion dependent thalassaemia’, Ministry of Health Malaysia – Malaysian Society of Paediatric Haematology & Oncology – Malaysian Paediatric Association – Academy of Medicine Malaysia.
- Ikeda K, Takeshita S, 2016. The role of osteoclast differentiation and function in skeletal homeostasis. *Journal of Biochemical*. 159:1–8.
- Jamuar SS, Lai AHM, 2012. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. *Therapeutic Advances in Hematology*. 3:299-307.
- Jeney V, 2017. Clinical Impact and Cellular Mechanisms of Iron Overload-Associated Bone Loss. *Frontier in Pharmacology*. 8:77.
- Jia P, Xu YJ, Zhang ZL, Li K, Li B, Zhang W, 2012. Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. *Journal of Orthopaedy Research*. 30:1843–1852.
- John NL. 1999. The thalassemia and related disorders: Quantitative disorders of hemoglobin synthesis; Wintrobe’s Clinical Hematology, tenth edition, Vol. I, chapter. 53: 1405–1448.

- Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S., 2007. Bone mineral density in beta-thalassemia major and intermedia. *Indian Pediatrics*. 1:29–32.
- Knovich MA, Storey JA, Coffman LG, dan Torti SV, 2009. Ferritin for the clinician. *Blood Reviews*. 23:95–104.
- Khero KN, Salih MM, 2013. Bone Mineral Density in beta thalassemia syndrome in Mosul city. *Annal of College of Medical Mosul*. 39: 160-165.
- Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J, 2008. Body iron metabolism and pathophysiology of iron overload. *International Journal of Hematology*. 88:7-15.
- Koperdanova M, Cullis JO, 2015. Interpreting raised serum ferritin levels. *British Medical Journal*. 351: h3692.
- Kwang JC., 2011. Bone Densitometry. Departement of Nuclear Medicine. *Seminars in Nuclear Medicine*. 41:220-228.
- Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S, Skordis N., 2008. Gender differences in the prevalence and severity of bone disease in thalassaemia. *Pediatric Endocrinology Reviews*. 6:116– 122.
- Lewiecki ME, Catherine M. Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi M, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S, 2008. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. *Bone*. 43:1115–1121.
- Majd Z, Haghpanah S, Ajami GH, Matin S, Namazi H, Bardestani M, Karimi M, 2015. Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion-dependent thalassemia. *Iranian Red Crescent Medical Journal*. 17(4): e24959
- Merchant R, Udani A, Puri V, D'cruz V, Patkar D, Karkera A, 2010. Evaluation of osteopathy in thalassemia by bone mineral densitometry and biochemical indices. *The Indian Journal of Pediatric*. 77:98791
- Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapadang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R, 2003. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. *Journal Clinical of Endocrinology Metabolism*. 88:3966-3972.
- Mahachoklertwattana P, Pootrakul P, Chuansumrit A, Choubtum L, Sriphrapadang A, Sirisriro R, Rajatanavin R, 2006. Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. *Journal of Bone and Mineral Metabolism*. 24:146–152
- Meena MC, Hemal A, Satija M, Arora SK, Bano S, 2015. Comparison of Bone Mineral Density in Thalassemia Major Patients with Healthy Controls. *Advances in Hematology*. e648349.
- Monis EL, Mannstadt M, 2015. Hypoparathyroidism–disease update and emerging treatments. *Annales d'Endocrinologie*, 76:84–88.

- Moore C Jr, Ormseth M, Fuchs H, 2013. Causes and significance of markedly elevated serum ferritin levels in an academic medical center. *Journal of Clinical Rheumatology*. 19:324-328.
- Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N, 2002. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. *Osteoporosis Internasional*. 13:644-649.
- Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N. 2004. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. *Journal of Bone and Mineral Research*. 19:722-727.
- Murray RK, 2009. Chapter 46: free radicals and antioxidant nutrients. *Harper's Illustrated Biochemistry, 28nd edition*. Mc Graw Hill Companies, Inc
- Milne M, Quail JM, Rosen CJ, Baran DT, 2001. Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. *Journal of Cellular and Biochemical*. 81:229–240.
- Mirza1 F, Canalis E, 2015. Secondary osteoporosis: pathophysiology and management. *European Journal of Endocrinology*. 173:131–151.
- Mishra AK, Tiwari A, 2013. Iron Overload in Beta Thalassaemia Major and Intermedia Patients. *MAEDICA – a Journal of Clinical Medicine*. 8:328-332.
- Nakanishi K dan Kinjo M, 2015. Hyperferritinemia and fever in adults. *Arthritis & Rheumatology* 67 (suppl 10)
- Nakhakes C, Jaruluxanananb S, Saengsudac Y, Saengsudac S, 2015. Risk factors for osteoporosis and the relationship between osteoporosis and hemoglobin level in adult patients with thalassemia in Rajavithi hospital. *Asian Biomedicine*. 9:169-174.
- Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R, Choudhry VP, 2017. Fractures and Low Bone Mineral Density in Patients with Beta Thalassemia Major. *Indian Society of Haematology & Transfusion Medicine*. 34:163–165.
- Nesheli HM, Farahanian E, 2016. Relation between bone mineral density and serum ferritin levels in patients with thalassemia major. *Caspian Journal of Pediatrics*. 2:158-63.
- NIH, 2001. Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. *Osteoporosis prevention, diagnosis, and therapy*. 285:785–795.
- Olthof AW, Sijens PE, Kreeftenberg HG, Kappert P, Irwan R, van der Jagt EJ, Oudkerk M, 2007. Correlation between serum ferritin levels and liver iron concentration determined by MR imaging: impact of hematologic disease and inflammation', *Magnetic Resonance Imaging*. 25:228-231.
- Panwar B, Gutiérrez OM, 2016). Disorders of iron metabolism and anemia in chronic kidney disease. *Seminars in Nephrology*. 36:252-261.
- Pemde HK, Chandra J, Gupta D, Singh V, Sharma R, Dutta AK, 2011. Physical growth in children with transfusion-dependent thalassemia. *Pediatric Health, Medicine and Therapeutics*. 2:13–19.

- Porter J, Viprakasit V, 2014. Iron overload and chelation', *Guidelines for The Management of Transfusion Dependent Thalassemia (TDT) 3th Edition*. Cappellini MD, Cohen A, Porter J, Taher A and Viprakasit V. Thalassemia International Federation TIF Publication no 20.
- Porter JB, Elalfy M, Taher A, Aydinok Y, Lee S, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A, 2016. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassemia. *European Journal of Haematology*. 98:280-288.
- Prabhu R, Prabhu V, Prabhu RS, 2009. Iron overload in beta thalassemia – A Reviewcd', *Journal of Bioscience and Technology*. 1:20-31.
- Prieto J, Barry M, Sherlock S, (1975). Serum ferritin in patients with iron overload and with acute and chronic liver diseases. *Gastroenterology*. 68:525-533.
- Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, Gasparini P, Siciliani MC, Iolascon A, 2000. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. *British Journal of Haematology*. 111:461-466.
- Pusat data dan informasi Kementrian Kesehatan RI. 2015. Data dan Kondisi Penyakit Osteoporosis. Jakarta: Kementrian Kesehatan RI.
- Pulungan AB, Himawan IW, Moelyo AG, 2018. Pubertas Normal dan Gangguannya. *Buku Ajar Endokrinologi. 2st Edition*. Jose RLB, Bambang TAAP and Aman BP. Badan Penerbit Ikatan Dokter Anak Indonesia. Jakarta.
- Ray PD, Wen HB, Tsuji Y, 2012. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signal*. 24:981–990.
- Rafsanjani KA, Razzaghy-Azar M, Zahedi-Shoolami L, Vossough P, Modarres A, Taheri N, 2009. Bone Mineral Density in β Thalassemia Major and Intermedia, Correlation with Biochemical and Hormonal Profiles. *Iranian of Blood and Cancer*. 4: 121-127.
- Rejeki DSS, Nurhayati N, Supriyanto, Kartikasari E, 2012. Studi Epidemiologi Deskriptif Talasemia. *Kesmas Nasional Public Health Journal*. 7:3.
- Riggs BL, Khosla S, Melton LJ III, 1998. A unitary model for involutinal osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. *Journal of Bone and Mineral Disease*. 13:763–773.
- Rosario C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y, 2013. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. *BMC Medicine* 11:185.
- Roodman GD, 2009. Osteoclasts pump iron. *Cell Metabolism*. 9:405–406.
- Rosen CJ, 2017. The Epidemiology and Pathogenesis of Osteoporosis. *Comprehensive Free Online Endocrinology Book*. www.endotext.org

- Sackett K, Cunderlik M, Sahni N, Killeen AA, Olson AP, 2016. Extreme hyperferritinemia: causes and impact on diagnostic reasoning. *American Journal of Clinical Pathology* 145:646-650.
- Saxena A, 2003. Growth retardation in thalassemia major patients. *International Journal of Human Genetic*. 3:237–246.
- Salvatore D, Davies TF, Schlumberger M, Hay ID, Larsen PR, 2016. Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In: Williams Textbook of Endocrinology. Editor : Melmed, S., Polonsky, K. S., & Larsen, P. R. Elsevier. Philadelphia: 334–365.
- Saliba AN, Harb AR, Taher AT, 2015. iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. *Journal of Blood Medicine*. 6: 197–209.
- Sinnot BP, 2018. Hypoparathyroidism – Review of the Literature. *Journal of Rare Disorders: Diagnosis & Therapy*. 4:12.
- Shoback DM, Strewler GJ, 1997. Disorders of the parathyroids and calcium metabolism. *Pathophysiology of Disease an Introduction to Clinical Medicine 7th edition*, Lange Medical Book chapter 17:397-422.
- Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, Peacock M, Raffaelli M, Silva BC, Thakker RV, Vokes T, Bouillon R, 2016. Presentation of hypoparathyroidism: etiologies and clinical features. *Journal of Clinical Endocrinology Metabolism*. 101:2300–2312.
- Singh K, Kumar R, Shukla A, Phadke SR, Agarwal S, 2012. Status of 25-hydroxyvitamin D deficiency and effect of vitamin D receptor gene polymorphisms on bone mineral density in thalassemia patients of North India. *Hematology*. 17:291-296.
- Smith RA, Cokkides V, Eyre HJ, 2006. American Cancer Society guidelines for the early detection of cancer. *CA : a cancer journal for clinicians*. 56:11-25.
- Snyder CK, 2015. Hypoparathyroidism in Children. *The Pediatric Endocrinology Nursing Society*
- Suratmadji G, Ashariati A, Sedana MP, Ugroseno, 2012. Profil perubahan penderita thalassemia β mayor yang diterapi desferoksamin infus kontinyu subkutan. Penelitian karya akhir SMF Ilmu penyakit Dalam FK UNAIR RSUD Dr Soetomo, 2012.
- Sutton VR, Stubna A, Patschkowski T, Munck E, Beinert H, Kiley PJ, 2004. Superoxide destroys the $[2\text{Fe-2S}]^{2+}$ cluster of FNR from Escherichia coli. *Biochemistry*. 43:791-798.
- Skordis N, Toumba M, 2011. Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects. *Pediatric Endocrinology Reviews*. 2:300-306.
- Srisukh S, Ongphiphadhanakul B, Bunnag P, 2016. Hypogonadism in thalassemia major patients. *Journal of Clinical & Translational Endocrinology*. 5:42–44.
- Takahashi N, Udagawa N, Suda T., 2014. Vitamin D endocrine system and osteoclasts. *BoneKEy Reports*. 3: 495.

- Taghizadeh SR, Moradveisi B, Kompany F, Ghaderi E, (2016). Correlation between heart and liver iron levels measured by MRI T2* and serum ferritin in patients with β -thalassemia major. *International Journal of Pediatrics*. 4:1559-1567.
- Taher A, El Rassi F, Isma'eel H, Koussa S, Inati A, Cappellini MD, 2008. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. *Haematologica*. 93:1584-1586.
- Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B, 2000. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload. *British Journal of Haematology*. 110:971–977.
- Tehrani MRH, Hamidieh AA, Naghghash A, Behfar M, Alimoghaddam K, Mohseni F, Rashidian H, Ghavamzadeh A, Shirazi S, Aboee-Rad M, Pajouhi M, Larijani B, Hamidi Z, 2019. How Thalassemia Affect Endocrinological, BMD and Bone Metabolism Parameters - A Cross Sectional Study. *Annals of Clinical and Laboratory Research*. 1:293.
- Tiosano D, Hochberg Z, 2001. Endocrine complications of thalassemia. *Journal of Endocrinological Investigation*. 24:716-723.
- Toumba M, Skordis N., 2010. Osteoporosis Syndrome in Thalassaemia Major : An Overview. *Journal of Osteoporosis*. 7:1-7.
- Teitelbaum SL, and Ross FP, 2003. Genetic regulation of osteoclast development and function. *Nature Review Genetics*. 4:638–649.
- Tsay J, Yang Z, Ross, FP, Cunningham-Rundles S, Lin H, Coleman R, 2010. Bone loss caused by iron overload in a murine model: importance of oxidative stress. *Blood*. 116:2582–2589.
- Viprakasit V, Origa R, 2014. Genetic basis, pathophysiology and diagnosis', *Guidelines for The Management of Transfusion Dependent Thalassemia (TDT) 3th Edition*. Cappellini MD, Cohen A, Porter J, Taher A and Viprakasit V. Thalassemia International Federation TIF Publication no 20.
- Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ, 2006. Prevalence of fractures among the Thalassemia syndromes in North America. *Bone*. 38: 571–575.
- Virgiliis De S, Congia M, Frau D, Argioluta F, Dianaa G, Cuccaa F, Varsia A, Sannaa G, Poddaa G, Foddea M, Pirastua GF, Caoa A., 1988. "Deferoxamine induced growth retardation in patients with thalassemia major," *Journal of Pediatrics*. 4:661–669.
- Voskaridou E, Terpos E, 2004. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. *British Journal of Haematology*. 127:127–139.
- Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV, 2010). Serum ferritin: past, present and future. *Biochimica et Biophysica Acta*. 1800: 760–769.
- Wahidiyat I, 2016. Thalassemia dan Permasalahannya di Indonesia. *Sari Pediatri*, 5: 2-3.

- Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y, 2009. Oxidative stress in bone remodeling and disease. *Trends in Molecular Medicine*. 15:10.
- WHO, 2003. Prevention And Management Of Osteoporosis : Report Of A WHO Scientific Group. WHO technical report series. 921:57
- Wang Y, Branicky R, Noe A, Hekimi S, 2018. Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling', *Journal of Cell Biology*. 17:1915-1928.
- Weatherall DJ, 2003. The hereditary anaemias. *ABC of Clinical Haematology: Second Edition*. BMJ Books
- Wells F, 2008. Haematologic investigations. *The Science of laboratory Diagnosis: Second Edition*, Edited by David Burnett and John Crocker; John Wiley & Sons Ltd ; 317-319.
- Wong P, Fuller PJ, Gillespie MT, Milat F, 2016. Bone disease in thalassemia: A molecular and clinical overview. *Endocrine Reviews*. 37: 320–346.
- Worwood M, 2007. Indicators of the iron status of populations: ferritin. In WHO/CDC. *Assessing the iron status of populations: report of a joint World Health Organization/ Centers for Disease Control and Prevention technical consultation on the assessment of iron status at the population level*. 2nd edn. World Health Organization, Geneva; 2007
- Xing W, Govoni KE, Donahue LR, Kesavan C, Wergedal J, Long C, Bassett JH, Gogakos A, Wojcicka A, Williams GR, Mohan S, 2012. Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice. *Journal of Bone Mineral Research*. 27:1067–1079.
- Yousefzadeh P, Shapses SA, Wang X, 2014. Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions. *International Journal of Endocrinology* vol 2014, article ID 981581
- Zhao G, Monier-Faugere MC, Langub MC, 2000. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferation. *Endocrinology*. 141:2674–2682.
- Zaidi M, 2007. Skeletal remodeling in health and disease. *Nature Medicine*. 13:791–801.